Adverum stock rating downgraded to Neutral by Chardan after Eli Lilly deal
NegativeFinancial Markets

Adverum's stock rating has been downgraded to Neutral by Chardan following its recent deal with Eli Lilly. This change reflects concerns about the future performance of Adverum in light of the partnership, which could impact investor confidence and market perception. Understanding these shifts is crucial for stakeholders as they navigate the evolving landscape of biopharmaceutical collaborations.
— Curated by the World Pulse Now AI Editorial System



